Related Experiment Video
Updated: Aug 15, 2026
07:20
Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
Published on: August 9, 2024
Pharmacologic interventions for reducing spasticity in cerebral palsy
Dilip R Patel1, Olufemi Soyode
1Michigan State University, Kalamazoo Center for Medical Studies, Kalamazoo, Michigan 49008, USA. patel@kcms.msu.edu
Indian Journal of Pediatrics
|November 8, 2005
Summary
Cerebral palsy (CP) spasticity management requires careful consideration. Both non-pharmacologic and pharmacologic interventions are available to improve motor function in children with CP.
Area of Science:
- Neurology
- Pediatrics
- Rehabilitation Medicine
Background:
- Motor dysfunction, particularly spasticity, is a hallmark of cerebral palsy (CP).
- Spasticity, characterized by velocity-dependent resistance to passive movement, presents unique challenges in CP management.
- The impact of spasticity varies, potentially hindering or aiding motor abilities like posture and ambulation.
Purpose of the Study:
- To review non-pharmacologic and pharmacologic interventions for reducing spasticity in children with cerebral palsy.
- To highlight the importance of individualized treatment strategies based on spasticity's impact.
Main Methods:
- Review of non-pharmacologic interventions: physiotherapy, occupational therapy, adaptive equipment, orthopedic surgery, neurosurgery.
- Review of pharmacologic interventions: oral medications (baclofen, diazepam, dantrolene, tizanidine), intrathecal baclofen, and local injections (botulinum toxin, phenol, alcohol).
Main Results:
- Non-pharmacologic approaches offer diverse strategies for spasticity management.
- Pharmacologic options provide targeted treatments for spasticity reduction.
- Treatment decisions must balance potential benefits and drawbacks of each intervention.
Conclusions:
- Comprehensive management of spasticity in cerebral palsy involves a multidisciplinary approach.
- Tailoring interventions to individual patient needs is crucial for optimizing outcomes.
- Further research into the efficacy and comparative effectiveness of different spasticity treatments is warranted.
Related Concept Videos
01:29Spasmolytic Agents: Chemical Classification
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...